NCT05192356View on ClinicalTrials.gov

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(3)

PHASE1CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

February 23, 2022

Primary Completion Date

May 8, 2022

Study Completion Date

June 8, 2022

Conditions
Hypertension and Dyslipidemia
Interventions
DRUG

CKD-348(3)

QD, PO

DRUG

CKD-828, D097, D337

QD, PO

Trial Locations (1)

08779

H Plus Yangji Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Chong Kun Dang Pharmaceutical

INDUSTRY

NCT05192356 - A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(3) | Biotech Hunter | Biotech Hunter